125 related articles for article (PubMed ID: 9683814)
1. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.
Schultz RM; Shih C; Wood PG; Harrison SD; Ehlhardt WJ
Oncol Rep; 1998; 5(5):1089-94. PubMed ID: 9683814
[TBL] [Abstract][Full Text] [Related]
2. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines.
Wagner MM; Paul DC; Shih C; Jordan MA; Wilson L; Williams DC
Cancer Chemother Pharmacol; 1999; 43(2):115-25. PubMed ID: 9923816
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.
Sessa C; Weigang-Köhler K; Pagani O; Greim G; Mora O; De Pas T; Burgess M; Weimer I; Johnson R
Eur J Cancer; 2002 Dec; 38(18):2388-96. PubMed ID: 12460783
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.
Panda D; DeLuca K; Williams D; Jordan MA; Wilson L
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9313-8. PubMed ID: 9689077
[TBL] [Abstract][Full Text] [Related]
6. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
Drew L; Fine RL; Do TN; Douglas GP; Petrylak DP
Clin Cancer Res; 2002 Dec; 8(12):3922-32. PubMed ID: 12473608
[TBL] [Abstract][Full Text] [Related]
7. Effect of albumin on antitumor activity of diarylsulfonylureas.
Schultz RM; Andis SL; Toth JE; Boder GB; Rinzel SM; Grindey GB
Anticancer Res; 1993; 13(6A):1939-43. PubMed ID: 8297099
[TBL] [Abstract][Full Text] [Related]
8. Preclinical anticancer activity of cryptophycin-8.
Corbett TH; Valeriote FA; Demchik L; Polin L; Panchapor C; Pugh S; White K; Knight J; Jones J; Jones L; LoRusso P; Foster B; Wiegand RA; Lisow L; Golakoti T; Heltzel CE; Ogino J; Patterson GM; Moore RE
J Exp Ther Oncol; 1996 Mar; 1(2):95-108. PubMed ID: 9414393
[TBL] [Abstract][Full Text] [Related]
9. Cellular uptake of a novel cytotoxic agent, cryptophycin-52, by human THP-1 leukemia cells and H-125 lung tumor cells.
Chen BD; Nakeff A; Valeriote F
Int J Cancer; 1998 Sep; 77(6):869-73. PubMed ID: 9714056
[TBL] [Abstract][Full Text] [Related]
10. Biological evaluation of cryptophycin 52 fragment A analogues: effect of the multidrug resistance ATP binding cassette transporters on antitumor activity.
Al-Awar RS; Corbett TH; Ray JE; Polin L; Kennedy JH; Wagner MM; Williams DC
Mol Cancer Ther; 2004 Sep; 3(9):1061-7. PubMed ID: 15367700
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the antitumor compound cryptophycin-52 with tubulin.
Panda D; Ananthnarayan V; Larson G; Shih C; Jordan MA; Wilson L
Biochemistry; 2000 Nov; 39(46):14121-7. PubMed ID: 11087360
[TBL] [Abstract][Full Text] [Related]
12. A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.
Al-Awar RS; Ray JE; Schultz RM; Andis SL; Kennedy JH; Moore RE; Liang J; Golakoti T; Subbaraju GV; Corbett TH
J Med Chem; 2003 Jul; 46(14):2985-3007. PubMed ID: 12825938
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer.
D'Agostino G; del Campo J; Mellado B; Izquierdo MA; Minarik T; Cirri L; Marini L; Perez-Gracia JL; Scambia G
Int J Gynecol Cancer; 2006; 16(1):71-6. PubMed ID: 16445613
[TBL] [Abstract][Full Text] [Related]
14. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
Smith CD; Zhang X; Mooberry SL; Patterson GM; Moore RE
Cancer Res; 1994 Jul; 54(14):3779-84. PubMed ID: 7913408
[TBL] [Abstract][Full Text] [Related]
15. Protein-binding patterns of the antitumor antibiotic cryptophycin 52 as measured with a two-phase partitioning system.
Kessel D
J Chromatogr B Biomed Sci Appl; 1999 Nov; 735(1):121-6. PubMed ID: 10630897
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.
Boinpally RR; Polin L; Zhou SL; Jasti BR; Wiegand RA; White K; Kushner J; Horwitz JP; Corbett TH; Parchment RE
Cancer Chemother Pharmacol; 2003 Jul; 52(1):25-33. PubMed ID: 12739061
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of cryptophycins: effect of infusion time and combination studies.
Menon K; Alvarez E; Forler P; Phares V; Amsrud T; Shih C; Al-Awar R; Teicher BA
Cancer Chemother Pharmacol; 2000; 46(2):142-9. PubMed ID: 10972484
[TBL] [Abstract][Full Text] [Related]
18. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides.
Shih C; Teicher BA
Curr Pharm Des; 2001 Sep; 7(13):1259-76. PubMed ID: 11472266
[TBL] [Abstract][Full Text] [Related]
19. Enantioselective synthesis of (+)-cryptophycin 52 (LY355703), a potent antimitotic antitumor agent.
Ghosh AK; Swanson L
J Org Chem; 2003 Dec; 68(25):9823-6. PubMed ID: 14656116
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.
Panda D; Himes RH; Moore RE; Wilson L; Jordan MA
Biochemistry; 1997 Oct; 36(42):12948-53. PubMed ID: 9335554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]